Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
American Journal of Clinical Pathology · 03.09.2024 · 162 (3) · 314-326
DOI: 10.1093/ajcp/aqae038 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 20.04.2024. Verfasst von Lyanne A Delgado-Coka und 16 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pathology. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Biomarkers, Tumor, Keratin-17. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Objectives
To determine the role of keratin 17 (K17) as a predictive biomarker for response to chemotherapy by defining thresholds of K17 expression based on immunohistochemical tests that could be used to optimize therapeutic intervention for patients with pancreatic ductal adenocarcinoma (PDAC).
Methods
We profiled K17 expression, a hallmark of the basal molecular subtype of PDAC, by immunohistochemistry in 2 cohorts of formalin-fixed, paraffin-embedded PDACs (n = 305). We determined a K17 threshold of expression to optimize prognostic stratification according to the lowest Akaike information criterion and explored the potential relationship between K17 and chemoresistance by multivariate predictive analyses.
Results
Patients with advanced-stage, low K17 PDACs treated using 5-fluorouracil (5-FU)–based chemotherapeutic regimens had 3-fold longer survival than corresponding cases treated with gemcitabine-based chemotherapy. By contrast, PDACs with high K17 did not respond to either regimen. The predictive value of K17 was independent of tumor mutation status and other clinicopathologic variables.
Conclusions
The detection of K17 in 10% or greater of PDAC cells identified patients with shortest survival. Among patients with low K17 PDACs, 5-FU–based treatment was more likely than gemcitabine-based therapies to extend survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Pathology.
- Departments of Preventative Medicine, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, US.
- Department of Pathology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia.
- Center for Applied Proteomics and Molecular Medicine, George Mason University, Fairfax, VA, US.
- Perthera, McLean, VA, US.
- Scientific and Medical Affairs, Pancreatic Cancer Action Network, Manhattan Beach, CA, US.
ORCID-Profile: Lynn M Matrisian, Brent K Larson
Förderung
- NCI NIH HHS
Zitieren
APA
Delgado-Coka, L. A., Roa-Peña, L., Babu, S., Horowitz, M., Petricoin, E. F., Matrisian, L. M., Blais, E. M., Marchenko, N., Allard, F. D., Akalin, A., Jiang, W., Larson, B. K., Hendifar, A. E., Picozzi, V. J., Choi, M., Shroyer, K. R., & Escobar-Hoyos, L. F. (2024). Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. American Journal of Clinical Pathology, 162(3), 314-326. https://doi.org/10.1093/ajcp/aqae038
Vancouver
Delgado-Coka LA, Roa-Peña L, Babu S, Horowitz M, Petricoin EF, Matrisian LM, et al. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. American Journal of Clinical Pathology. 2024;162(3):314-326. doi:10.1093/ajcp/aqae038
BibTeX
@article{DelgadoCoka2024,
author = {Delgado-Coka, Lyanne A and Roa-Peña, Lucia and Babu, Sruthi and Horowitz, Michael and Petricoin, Emanuel F and Matrisian, Lynn M and Blais, Edik M and Marchenko, Natalia and Allard, Felicia D and Akalin, Ali and Jiang, Wei and Larson, Brent K and Hendifar, Andrew E and Picozzi, Vincent J and Choi, Minsig and Shroyer, Kenneth R and Escobar-Hoyos, Luisa F},
title = {Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma},
journal = {American Journal of Clinical Pathology},
year = {2024},
volume = {162},
number = {3},
pages = {314--326},
doi = {10.1093/ajcp/aqae038}
}
EUVIMED